All In Biotech

Drug Trial Radar · NCT04950764

An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment

Last checked: Nov 20, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

Nov 16, 2021

Primary completion

Feb 24, 2025

Study completion Feb 27, 2025

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Jul 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Participants with Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

Conditions

  • Primary Biliary Cholangitis
  • Compensated Cirrhosis
  • Hepatic Impairment

Interventions

  • SeladelparDrug

    Tablets Administered Orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Pharmacokinetic (PK) Parameter: Cmax of Seladelpar and Its Metabolites (M1, M2, and M3)Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
  2. Part A: PK Parameter: Tmax of Seladelpar and Its Metabolites (M1, M2, and M3)Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
  3. Part A: PK Parameter: AUC0-t of Seladelpar and Its Metabolites (M1, M2, and M3)Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
  4. Part A: PK Parameter: AUC0-inf of Seladelpar and Its Metabolites (M1, M2, and M3)Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
  5. Part B: PK Parameter: Cmax of Seladelpar and Its Metabolites (M1, M2, and M3)Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose
  6. Part B: PK Parameter: Cmax,ss of Seladelpar and Its Metabolites (M1, M2, and M3)Time frame: Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose
  7. Part B: PK Parameter: Tmax of Seladelpar and Its Metabolites (M1, M2, and M3)Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose
  8. Part B: PK Parameter: Tmax,ss of Seladelpar and Its Metabolites (M1, M2, and M3)Time frame: Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose
  9. Part B: PK Parameter: AUC0-24 of Seladelpar and Its Metabolites (M1, M2, and M3)Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose
  10. Part B: PK Parameter: AUC0-tau of Seladelpar and Its Metabolites (M1, M2, and M3)Time frame: Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose
  11. Part B: PK Parameter: RCmax of Seladelpar and Its Metabolites (M1, M2, and M3)Time frame: Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose
  12. Part B: PK Parameter: RAUC0-t of Seladelpar and Its Metabolites (M1, M2, and M3)Time frame: Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose
  13. Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) and Study Drug-Related TEAEsTime frame: Part A: Up to Week 5; Part B: Up to Week 8
  14. Percentage of Participants Who Experienced Any Grade and Grade 3 or 4 TEAEsTime frame: Part A: Up to Week 5; Part B: Up to Week 8
  15. Percentage of Participants Who Experienced TEAEs of Special InterestTime frame: Part A: Up to Week 5; Part B: Up to Week 8
  16. Percentage of Participants With Clinically Significant Changes in Vital SignsTime frame: Part A: Up to Day 4; Part B: Up to Day 31
  17. Percentage of Participants With Abnormal Clinically Significant 12-Lead Electrocardiogram (ECG) FindingsTime frame: Part A: Up to Day 4; Part B: Up to Day 28
  18. Percentage of Participants Who Experienced Laboratory AbnormalitiesTime frame: Part A: Up to Day 4; Part B: Up to Day 31

Locations

20 sites in 4 countries. Site status is shown where the registry gives one.

  • Arizona Liver Health

    Chandler, Arizona

  • University of California Davis

    Sacramento, California

  • University of Colorado Anschutz

    Aurora, Colorado

  • Mercy Medical Center

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Henry Ford Health System

    Novi, Michigan

  • Southern Therapy and Advanced Research LLC

    Jackson, Mississippi

  • Weill Medical College of Cornell University

    New York, New York

  • The Liver Institute at Methodist Dallas Medical Center

    Dallas, Texas

  • American Research Corporation

    San Antonio, Texas

  • Pinnacle Clinical Research- SA

    San Antonio, Texas

  • Pusan National University Hospital

    Busan, South Korea

  • Inje University Busan Paik Hospital

    Busan, South Korea

  • Kyungpook National University Hospital

    Daegu, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital Yonsei University Health System

    Seoul, South Korea

  • Hospital General Universitario Gregorio Maran

    Madrid, Spain

  • NIHR BRC Centre for Liver and Gastrointestinal Research Birmingham

    Birmingham, United Kingdom

  • The Royal Free London NHS Foundation Trust

    London, United Kingdom

  • Kings College Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.